A VS IQV Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

A
29/100

A returned -20.34% in the last 12 months. Based on SPY's performance of -16.79%, its performance is below average giving it a score of 28 of 100.

IQV
91/100

IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.

Analyst Price Targets

A
82/100

14 analysts offer 12-month price targets for A. Together, they have an average target of 167.75, the most optimistic target put A at 170 within 12-months and the most pessimistic has A at 161.

IQV
69/100

17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.

Sentiment

A
69/100

A had a bullish sentiment score of 69.50% across Twitter and StockTwits over the last 12 months. It had an average of 77.66 posts, 409.66 comments, and 1,364.19 likes per day.

IQV

"Sentiment" not found for IQV

Technicals

A
50/100

A receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

IQV
75/100

IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Earnings

A
100/100

A has missed earnings 0 times in the last 20 quarters.

IQV
100/100

IQV has missed earnings 0 times in the last 20 quarters.

Profit

A
79/100

Out of the last 20 quarters, A has had 20 profitable quarters and has increased their profits year over year on 10 of them.

IQV
88/100

Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.

Volatility

A
52/100

A has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

IQV
49/100

IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Dividend

A
48/100

A's most recent dividend was $0.15 per share, based on a share price of $109.02. It was a payout ratio of 24.10% compared to their total earnings.

IQV

"Dividend" not found for IQV

All score calculations are broken down here to help you make more informed investing decisions

Agilent Technologies Inc. Summary

New York Stock Exchange / A
Healthcare
Medical - Diagnostics & Research
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

IQVIA Holdings Inc. Summary

New York Stock Exchange / IQV
Healthcare
Medical - Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.